Back to Awarded Treatment Trials


Awarded Trial: 02T-241

Grant ID

02T-241

Illness

Schizophrenia and Alcohol Dependence

Primary Drug/Intervention

Glycine

Primary Dosage

60 grams

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Petrakis

Sample Size

46

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

Alcohol use, PANSS, CDS, movement disorder scales, quality of life scales, cognitive battery

Results

This trial randomized 20 patients with schizophrenia and alcohol abuse to glycine or placebo plus their regular medication for 12 weeks. The primary outcome was alcohol craving and drinking, and there were no differences between those on glycine or placebo. The secondary outcome was schizophrenia symptoms as measured by PANSS; patients on glycine had a nonsignificant reduction in both positive and negative symptoms.

Publication

N/A

Link

N/A

PI Name

Ismene Petrakis

Degree

MD

Center

VA CT Heatlhcare System, Research / 116 A

Institution

Yale University School of Medicine

Address

950 Campbell Ave

City or Town

West Haven

State or Province

CT

Zip or Postal Code

6516

Country

USA

Email Address

ismene.petrakis@yale.edu